Es Hcm Ugps1 Iv Fluids First Line

---
name: es-hcm-ugps1-iv-fluids-first-line
description: Recommends initiating intravenous isotonic saline hydration as initial management for hypercalcemia of malignancy (HCM) while awaiting antiresorptive therapy, with fluid rate adjusted according to cardiac function. Triggered when a clinician encounters a patient with HCM (e.g., serum calcium >12 mg/dL, symptoms of hypercalcemia) and seeks immediate measures before specific drugs are available.
---

# Administer IV fluids as first‑line therapy while awaiting antiresorptives

## STEP 1 — Gather Information
Collect serum calcium, symptom severity, cardiac history (known EF, signs of heart failure), volume status (JVP, peripheral edema), renal function (creatinine, urine output), and current medications.  
**Action:** If data obtained, proceed to assess suitability for fluid resuscitation.

## STEP 2 — Rule In / Rule Out
Is there evidence of volume overload or severe left ventricular dysfunction (e.g., pulmonary edema, EF < 30%, acute dyspnea at rest)?  
- **No:** Proceed with IV fluid resuscitation.  
- **Yes:** Avoid large bolus; consider a cautious fluid challenge (e.g., 250 mL NS over 1 h) with close monitoring or hold fluids and address overload first.  
**Action:** Based on the binary fork, decide whether to proceed with fluids or modify approach.

## STEP 3 — Classify or Stratify
Stratify by cardiac function to tailor infusion rate:  
- Normal/mildly reduced EF ≥ 40%: Standard rate 200–500 mL/h.  
- Moderate reduction EF 30–39%: Reduced rate 100–200 mL/h.  
- Severe EF < 30% or overt HF: Minimal rate ≤100 mL/h, avoid bolus, monitor for overload.  
**Action:** Select the appropriate infusion rate based on this classification.

## STEP 4 — Decide
Administer an initial isotonic saline bolus of 1–2 L (if no contraindication from Step 2), then continue at the rate determined in Step 3. Aim for urine output 100–150 mL/h, reassess serum calcium and volume status every 4–6 h, and prepare to start antiresorptive therapy (e.g., zoledronic acid or denosumab) as soon as available.  
**Action:** Initiate fluids and monitor for response.

## Clinical Guardrails / Mimics / Pitfalls
Do not give large fluid boluses in patients with known pulmonary edema, severe systolic dysfunction, or anuria; avoid excessive fluids in renal failure without monitoring; do not delay antiresorptives in severe HCM (SCa > 14 mg/dL) without adding calcitonin; avoid routine loop diuretics unless volume overload develops; monitor for hypokalemia and hypophosphatemia during hydration.

## Concrete Clinical Example
A 68‑year‑old with metastatic lung cancer presents with fatigue, nausea, and serum calcium 13.8 mg/dL. Echocardiogram shows EF 50%, no pulmonary edema. Step 1: labs and vitals obtained. Step 2: no volume overload → proceed. Step 3: EF ≥ 40% → select 250 mL/h. Step 4: give 1 L NS bolus, then 250 mL/h targeting urine output 120 mL/h. Calcium falls to 11.5 mg/dL after 12 h; zoledronic acid is started thereafter.

**Source:** Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac621